期刊文献+

血清半乳糖凝集素-3水平与慢性心力衰竭患者预后关系的Meta分析 被引量:4

Prognostic significance of serum galectin-3 level in chronic heart failure:a Meta analysis
原文传递
导出
摘要 目的:评价血清半乳糖凝集素-3(galectin-3)水平与慢性心力衰竭(chronic heart failure,CHF)患者预后之间的关系。方法检索Pubmed、Embase、Cochrane图书馆、中国生物医学文献数据库、中国知网、万方等数据库,筛选关于半乳糖凝集素-3与CHF预后关系的中英文文献,提取风险比(hazard ratio, HR)及其95%可信区间(confidence interval,CI)。对纳入的文献进行质量评价,采用STATA 12.0软件进行Meta分析。结果纳入6篇符合要求的文献,异质性检验表明研究具有异质性,随机效应模型合并统计量显示在未排除其他影响因素的情况下,半乳糖凝集素-3预测CHF的HR=1.63,95%CI 1.26~2.11;排除其他影响因素后,HR=1.23,95%CI 1.07~1.42。结论高水平半乳糖凝集素-3可能是CHF不良预后的独立危险因素。 Objective To evaluate the relation between serum galectin-3 level and chronic heart failure (CHF) prognosis. Methods Articles which involved relation between galectin-3 and CHF prognosis were searched in Pubmed, Embase, Cochrane Library, Chinese Biomedical Literature Database, CNKI and WANFANG Databases. Hazard ratio (HR) and 95%confidence interval (CI) in each literature were extracted for meta-analysis using STATA 12.0 software. Results Six literature complying with the requirements were included. Heterogeneity test showed that heterogeneity exists in different studies, and statistics were combined using a random effects model. Under the influence of other factors, the combined HR was 1.63 and 95%CI was 1.26-2.11. When the influence of other factors were excluded, the combined HR was 1.23 and 95%CI was 1.07-1.42. Conclusion High serum level of galectin-3 may be an independent risk factor for poor prognosis of CHF patients.
出处 《中华临床医师杂志(电子版)》 CAS 2013年第23期212-214,共3页 Chinese Journal of Clinicians(Electronic Edition)
基金 国家自然科学基金(81300070 81270303)
关键词 半乳糖凝集素-3 心力衰竭 预后 META分析 全因死亡率 GALECTIN 3 Heart failure Prognosis Meta-analysis All cause mortality
  • 相关文献

参考文献15

  • 1Shah AM,Mann DL. In search of new therapeutic targets and strategies for heart failure:recent advances in basic science[J].{H}LANCET,2011.704-712. 被引量:1
  • 2Bui AL,Horwich TB,Fonarow GC. Epidemiology and risk profile of heart failure[J].Nat Rev Cardiol,2011.30-41. 被引量:1
  • 3Gonzalez A,Ravassa S,Beaumont J. New targets to treat the structural remodeling of the myocardium[J].{H}Journal of the America College of Cardiology,2011.1833-1843. 被引量:1
  • 4Karayannis G,Triposkiadis F,Skoularigis J. The Emerging Role of Galectin-3 and ST2 in Heart Failure:Practical Considerations and Pitfalls Using Novel Biomarkers[J].Curr Heart Fail Rep,2013.441-449. 被引量:1
  • 5Hrynchyshyn N,Jourdain P,Desnos M. Galectin-3:A new biomarker for the diagnosis,analysis and prognosis of acute and chronic heart failure[J].Arch Cardiovasc Dis,2013.541-546. 被引量:1
  • 6Chen K,Jiang RJ,Wang CQ. Predictive value of plasma galectin-3 in patients with chronic heart failure[J].{H}European Review for Medical and Pharmacological Science,2013.1005-1011. 被引量:1
  • 7Tang WH,Shrestha K,Shao Z. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival[J].{H}American Journal of Cardiology,2011.385-390. 被引量:1
  • 8Lok DJ,Klip IT,Lok SI. Incremental prognostic power of novel biomarkers(growth-differentiation factor-15,high-sensitivity C-reactive protein,galectin-3,and high-sensitivity troponin-T)in patients with advanced chronic heart failure[J].{H}American Journal of Cardiology,2013.831-837. 被引量:1
  • 9Lok DJ,Van Der Meer P,de la Porte PW. Prognostic value of galectin-3,a novel marker of fibrosis,in patients with chronic heart failure:data from the DEAL-HF study[J].{H}CLINICAL RESEARCH IN CARDIOLOGY,2010.323-328. 被引量:1
  • 10de Boer RA,Lok DJ,Jaarsma T. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction[J].{H}Annals of Medicine,2011.60-68. 被引量:1

同被引文献37

  • 1樊君,石奇,尚红伟,李海瑞,李振东,高续春.环磷酸腺苷的研究进展[J].中国现代应用药学,2005,22(z1):597-599. 被引量:9
  • 2杜军保,齐建光.肺动脉高压发病机制的新进展[J].武警医学,2006,17(11):803-806. 被引量:2
  • 3Pal SN,Kofidis T.New cell therapies in cardiology[J].Expert Rev Cardiovasc Ther,2012,10(8):1023-1037. 被引量:1
  • 4Emdin M,Vittorini S,Passino C.Old and new biomarkers of heart failure[J].Eur J Heart Fail,2009,11(4):331-335. 被引量:1
  • 5Eurlings LW,Sanders-van Wijk S,van Kimmenade R,et al.multimarker strategy for short-term risk assessment in patients with dyspnea in the Emergency Department[J].Am Coll Cardiol,2012,60(17):1668-1677. 被引量:1
  • 6Bayes-Genis A,de Antonio M,Vila J,et al.Head-to-Head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification[J].J Am Coll of Cardiol,2014,63(2):158-166. 被引量:1
  • 7Felker GM,Fiuzat M,Shaw LK,et al.Galectin-3 in ambulatory patients with heart failure:results from the HFACTION study[J].Circ Heart Fail,2012,5(1):72-78. 被引量:1
  • 8Tang WH,Shrestha K,Shao Z,et al.Usefulness of plasma galectin-3levels in systolic heart failure to predict renal insufficiency and survival[J].Am J Cardiol,2011,108(3):385-390. 被引量:1
  • 9Lok DJ,Klip IT,Lok SI,et al.Incremental prognostic nower of Novel biomarkers(growth-differentiation factor-15,high-sensitivity C-reactive protein,galectin-3,and highsensitivity troponin-T)in patients with advanced chronic heart failure[J].Am J Cardiol,2013,112(6):831-837. 被引量:1
  • 10Ueland T,Aukrust P,Broch K,et al.Galectin-3in heart failure:high levels are associated with all-cause mortality[J].Int J Cardiol,2011,150(3):361-364. 被引量:1

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部